Last edition
News about "UK MHRA"
UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment
The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.
UK MHRA | 15/04/2026 | By News Bureau
CStone Pharmaceuticals Secures UK MHRA Approval for Sugemalimab in Stage III NSCLC
The UK Medicines and Healthcare products Regulatory Agency grants a new indication for sugemalimab monotherapy in unresectable Stage III NSCLC, expanding its European footprint and global commercial reach.
UK MHRA | 23/02/2026 | By News Bureau | 169
Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
UK MHRA | 10/02/2026 | By News Bureau | 133
UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk
UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.
UK MHRA | 07/02/2026 | By News Bureau | 487
Paracetamol Safe in Pregnancy, Confirms MHRA After Major Lancet Review Finds No Autism or ADHD Risk
The UK medicines regulator MHRA reaffirmed paracetamol as safe during pregnancy after a major Lancet review found no link to autism, ADHD or intellectual disability in children.
UK MHRA | 20/01/2026 | By News Bureau | 259
UK MHRA Approves up to 7.2 mg Dose of Semaglutide for Obesity Treatment
The UK MHRA has approved a higher dose of semaglutide of up to 7.2 mg for weight management in adult patients with obesity. The regimen involves three 2.4 mg injections and is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with a Body Mass Index (BMI) of 30 kg/m² or higher.
UK MHRA | 17/01/2026 | By News Bureau | 122
Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.
UK MHRA | 27/08/2025 | By Darshana | 228
Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution
The product will be manufactured at the plant of Bell, Sons & Co, UK
UK MHRA | 24/01/2023 | By Sudeep Soparkar | 580
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy